Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CRHBP | P24387 | 2/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6592622 | 0.90 | XDH (0.51) | XDH | |
| SCHEMBL6079485 | 0.86 | XDH (0.42) | XDHALDH1A1KDM4EHPGDCRHBP | |
| SCHEMBL6079319 | 0.81 | APP (0.45) | ALDH1A1NOTUM | |
| SCHEMBL17769171 | 0.80 | LMNA (0.50) | ALDH1A1HPGDNOTUM | |
| SCHEMBL6080510 | 0.79 | LMNA (0.47) | ALDH1A1HPGDNOTUM | |
| SCHEMBL6079903 | 0.79 | ALDH1A1 (0.44) | ALDH1A1HPGDTDP1NOTUM | |
| SCHEMBL6080651 | 0.78 | PTGER1 (0.42) | TDP1 | |
| SCHEMBL6081240 | 0.77 | LMNA (0.47) | ALDH1A1KDM4EHPGDNOTUM | |
| SCHEMBL6080128 | 0.77 | GAA (0.39) | ALDH1A1KDM4EHPGDCRHBPCRHR2 | |
| SCHEMBL6080214 | 0.77 | APP (0.43) | ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | XDH 128/4885ALDH1A1 2726/4885KDM4E 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.